Thursday, April 16

Epidural anaesthesia for caesarean delivery in a woman with Fontan circulation and severe thrombocytopaenia.

Signal observed of successful epidural anesthesia in a patient with Fontan circulation despite severe thrombocytopenia (<50×10⁹/L). Evidence suggests thromboelastography can guide neuraxial anesthesia decisions when platelet counts appear prohibitive, particularly in Fontan physiology where general anesthesia poses significant hemodynamic risks. Worth noting the multidisciplinary approach including targeted platelet transfusion and continuous invasive monitoring in this high-risk obstetric case.

Our case supports the feasibility of epidural anaesthesia even in severely thrombocytopenic patients, particularly when general anaesthesia carries significant haemodynamic risk as in Fontan circulation...

Relevance: Directly addresses Fontan circulation management with anticoagulation considerations, relevant to both the dx-fontan diagnosis and pediatric anticoagulation research interests.

Prognostic implications of single antiplatelet therapy in individuals developing diabetic foot disease with concurrent peripheral arterial disease.

Evidence suggests aspirin demonstrates comparable limb and cardiovascular outcomes with potentially favorable survival compared to clopidogrel or cilostazol in diabetic patients with peripheral arterial disease after foot events. Signal observed that both clopidogrel and cilostazol were associated with higher all-cause mortality risk versus aspirin in this high-risk population. Worth noting these findings support aspirin as a practical antiplatelet option for secondary prevention, though the study focused on adult diabetic populations rather than pediatric cardiac conditions.

These observational findings suggest aspirin is a practical antiplatelet option for secondary prevention in this high-risk population, though further precise trials are needed to verify.

Relevance: Studies antiplatelet therapy including aspirin (drug-aspirin in formulary), providing insights into antiplatelet management principles that inform pediatric practice.

Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India.

Signal observed of significant interaction between diabetes and educational attainment on heart failure mortality outcomes, with diabetes conferring 25% higher death risk in low-education patients versus 22% lower risk in higher-education patients. Evidence suggests educational attainment modifies the impact of diabetes on heart failure prognosis, highlighting social determinants as important mortality predictors. Worth noting this large registry study (10,850 patients) demonstrates the complex interplay between comorbidities and social factors in heart failure outcomes.

Public health strategies should prioritise health literacy and equitable access to care to reduce disparities and improve outcomes in vulnerable populations.

Relevance: Directly addresses heart failure research interest, examining mortality predictors and outcomes in heart failure patients with diabetes comorbidity.

Navigating Medication Risk in the ED: Communication Preferences of Older Adults Regarding Deprescribing.

Signal observed that 62% of older adults prefer emergency department-initiated 'therapeutic pause' of aspirin with primary care follow-up over generic deferral approaches after bleeding events. Evidence suggests patients are receptive to proactive deprescribing discussions in the ED setting, with therapeutic pause preferred over strict deprescribing recommendations. Worth noting this communication strategy may inform aspirin management decisions across care settings, including pediatric contexts where antiplatelet therapy requires careful risk-benefit assessment.

Our study suggests that ED physicians may take a proactive approach in addressing potential deprescribing in caring for patients with ADEs, such as initiating a...

Relevance: Related to drug-aspirin management and deprescribing considerations, though focused on geriatric rather than pediatric populations.

Impact of SGLT2 Inhibitors on Mortality Across Different Populations: A Systematic Review and Meta-Analysis.

Evidence suggests SGLT2 inhibitors provide consistent mortality reduction across both short-term (up to one year, RR 0.89) and long-term follow-up periods, with particular benefit in chronic heart failure and chronic kidney disease populations. Signal observed of early survival benefit when initiated during acute cardiac decompensation (RR 0.76). Worth noting the cardiovascular mortality reduction (RR 0.88) was most pronounced in chronic heart failure subgroups, though these findings apply to adult populations.

Future well-designed trials are needed to address the impact of less-explored SGLT2 inhibitors and understudied populations.

Relevance: Directly relevant to heart failure research interest, examining mortality outcomes and cardio-protective effects of SGLT2 inhibitors in heart failure populations.

[Tako-tsubo syndrome associated with apical intraventricular thrombus, complicated by peripheral embolism generated by the recovery of ventricular function].

Signal observed of left ventricular thrombus formation and peripheral embolism during the recovery phase of Tako-tsubo syndrome despite anticoagulation with sodium heparin. Evidence suggests the recovery phase represents a critical period for embolization risk, with increased thrombus mobility as ventricular function improves. Worth noting this case highlights the challenges of anticoagulation management in acute cardiomyopathy and the importance of serial echocardiographic monitoring.

TTS may be complicated by LVT and embolism even in anticoagulated patients, posing a clinical challenge in the absence of specific guidelines.

Relevance: Related to anticoagulation management and heart failure, demonstrating thromboembolic complications and anticoagulation challenges in acute cardiomyopathy.

Clinical Experience With the Occlutech Atrial Flow Regulator (Occlutech AFR) in a Failing Fontan Population

Signal observed of ongoing clinical investigation into the Occlutech Atrial Flow Regulator device for failing Fontan circulation across multiple pediatric centers. Evidence suggests this interventional approach is being evaluated as a treatment option for Fontan failure, with enrollment planned for 25 patients. Worth noting this multi-center study (Birmingham, Los Angeles, San Diego, Aurora, Peoria) represents active research into novel interventions for this complex single ventricle population.

Relevance: Directly addresses failing Fontan circulation, a primary diagnosis (dx-fontan) and major research interest (Fontan circulation, single ventricle outcomes) in the profile.